ArticleCell reports2022
KRAS
Abstract read
In one paragraph
Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Design of new drugs for medullary thyroid carcinoma.Frontiers in oncology · 2022Pooled it
- A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- D3S-001 in advanced solid tumors with KRASNature medicine · 2025Trial
- Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.Signal transduction and targeted therapy · 2025Trial
- Adagrasib with or without Cetuximab in Colorectal Cancer with MutatedThe New England journal of medicine · 2023Trial
- Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.Medical oncology (Northwood, London, England) · 2026Review
- RAS-targeted therapies for pancreatic cancer.ESMO gastrointestinal oncology · 2026Review
- Rewiring KRAS-driven cancers through the ubiquitin-proteasome system: therapeutic opportunities with a focus on deubiquitinase.Experimental & molecular medicine · 2026Review
- KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment.Biomarker research · 2026Review
- PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition.Cancer research · 2026Article
- CDK8 remodels the tumor microenvironment and promotes resistance to KRASThe EMBO journal · 2026Article
- Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.Journal of medicinal chemistry · 2026Article
- Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling.Cancer research communications · 2026Article
- Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond.Targeted oncology · 2026Review
- M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS.bioRxiv : the preprint server for biology · 2026Article
- Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer.Nature communications · 2026Article
- Targeting SHOC2: a treatable therapeutic site in RAS(Q61) mutant cancers.Science China. Life sciences · 2026Article
- Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Proteolysis-targeting chimera (PROTAC) in cancer: design principles and applications on "undruggable" targets.Biomarker research · 2026Review
- The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition.Cancer research · 2026Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Meagan B RyanMassachusetts General Hospital Cancer Center, 149 13(th) Street, 7(th) Floor, Boston, MA 02129, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Oluwadara CokerThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alexey SorokinThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Katerina FellaMassachusetts General Hospital Cancer Center, 149 13(th) Street, 7(th) Floor, Boston, MA 02129, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Haley BarnesMassachusetts General Hospital Cancer Center, 149 13(th) Street, 7(th) Floor, Boston, MA 02129, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Edmond WongMassachusetts General Hospital Cancer Center, 149 13(th) Street, 7(th) Floor, Boston, MA 02129, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Preeti KanikarlaThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fengqin GaoThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Youyan ZhangEli Lilly, Indianapolis, IN, USA.
Lian ZhouEli Lilly, Indianapolis, IN, USA.
Scott KopetzThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ryan B CorcoranMassachusetts General Hospital Cancer Center, 149 13(th) Street, 7(th) Floor, Boston, MA 02129, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: rbcorcoran@partners.org.
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MTissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI SHIVDASANI, RAMESH A · 2007 to 2023
$33.2MProject 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT · 2019 to 2023
$11.0MUniversity of Texas PDX Development and Trial CenterU54CA224065 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAMODARAN, SENTHILKUMAR, MERIC-BERNSTAM, FUNDA · 2017 to 2022
$7.7MProject 2U54CA224068 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CORCORAN, RYAN BRUCE, FLAHERTY, KEITH T · 2017 to 2021
$6.3MOvercoming adaptive feedback resistance to KRAS inhibition in colorectal cancerR01CA262805 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Ryan Bruce Corcoran, Scott Kopetz · 2022 to 2026
$3.5MTranslational Genomics and Precision Medicine in Cancer Training ProgramT32CA217789 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Subrata Sen · 2018 to 2026
$2.2MNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA127003NCI NIH HHS P50 CA221707NCI NIH HHS R01 CA262805NCI NIH HHS T32 CA217789NCI NIH HHS U54 CA224065NCI NIH HHS U54 CA224068
Abstract
Although KRAS has long been considered undruggable, direct KRAS
Indexed as
Proto-Oncogene Proteins p21(ras)AnimalsCell Line, TumorErbB ReceptorsFeedbackHumansMiceMitogen-Activated Protein KinasesMutationNeoplasmsSignal TransductionErbB ReceptorsKRAS protein, humanMitogen-Activated Protein KinasesProto-Oncogene Proteins p21(ras)adagrasibadaptive resistanceCP: CancerKRASKRASG12Csotorasib
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.